Nektar Therapeutics Cash Flow - Annual (NASDAQ:NKTR)

Add to My Stocks
$22.17 $0.51 (2.35%) NKTR stock closing price Jul 20, 2017 (Closing)

The Nektar Therapeutics cash flow statement helps investors understand how well the company is managing its cash flows. Financials statements like the income statement and balance sheet show that the company has Nektar Therapeutics profits and Nektar Therapeutics debt, while the cash flow statement provides details of cash flow movments. Nektar Therapeutics had cash and cash equivalents of $55.57M at beginning of year and $59.64M at year end for 2016. Nektar Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. The cash from operating activities for Nektar Therapeutics is $-117.02MĀ for 2016, which saw a decrease of 60.13% from previous year. View details of Nektar Therapeutics cash flows for latest & last ten financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Nektar Therapeutics Net Income Cash Flow
-153.52M-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M-32.76M
Depreciation Depletion Amortization Cash-Flow15.35M12.85M12.92M14.27M14.5M14.95M16.55M14.88M22.48M28.15M
Net Increase (Decrease) in Assets Liabilities7.93M-34.7M-116.42M90.58M1.6M-14.95M-64.65M117.7M-26.79M106.75M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net13.21M29.94M15.4M18.62M25.98M20.24M30.17M9.66M-107.14M44.15M
Nektar Therapeutics Net Cash from (used by) Operating Activities
-117.02M-73.08M-142M-38.52M-129.75M-113.74M-55.87M39.73M-145.78M146.3M
Increase (Decrease) in Prop Plant And Equipment-6.39M-11.19M-9.97M-4.09M-10.58M-9.72M-31.45M-20.7M-18.85M-32.79M
Acquisition Disposition of Subsidiaires--------4.44M114.83M-
Increase (Decrease) in Investments-76M-28.14M-27.59M54M148.6M-102.23M48.16M-123.89M178.67M0.14M
Other Cash Inflow (Outflow) from Investment Activities-25M---25M-----
Nektar Therapeutics Net Cash from (used by) Invesment Activities
-82.4M-14.33M-37.57M49.9M113.02M-111.95M16.71M-149.03M274.65M-32.65M
Issuance (Purchase) of Equity Shares209.56M32.2M163.52M8.2M4.11M224.31M8.89M4.82M0.38M3.78M
Issuance (Repayment) of Debt Securities-5.94M98.57M-3.53M-2.99M-96.9M-1.97M-1.35M-1.28M-50.12M-105.54M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities
Nektar Therapeutics Net Cash from (used by) Financing Activities
203.61M130.78M152.98M2.21M26.8M222.33M7.53M3.53M-49.74M-101.76M
Effect of Exchange Rate Changes on Cash-0.12M-0.15M-0.1M0.03M0.06M0.91M-0.21M-0.22M0.16M0.65M
Nektar Therapeutics Net Change in Cash & Cash Equivalents
4.07M43.2M-26.7M13.63M10.12M-2.44M-31.84M-105.98M79.29M12.53M
Cash & Equivalents at Beginning of Year55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M63.76M
Cash & Equivalents at Year End59.64M55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

1:22
NKTR
Nektar Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Nektar Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:
  • Net Change in Cash and Cash Equivalents: Nektar Therapeutics cash reduced YoY to $-153.52M, meaning the company is unable to meet its expenditure and grow cash which will also eventually reflect in the Nektar Therapeutics stock price movement.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Nektar Therapeutics lost $43.94M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc. , and was $-117.02M for NKTR in last year report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $203.61M for Nektar Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.
.

Key Financial Ratios For Nektar Therapeutics Cash Flow

FCF margin
-1.56